Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14703436 | 0.80 | SMN1; SMN2 (0.47) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL17777333 | 0.80 | LMNA (0.42) | KMT2AMAPTLMNAHPGDALDH1A1 | |
| SCHEMBL13939608 | 0.80 | KMT2A (0.56) | KMT2AMAPTLMNAALDH1A1MEN1 | |
| SCHEMBL14703344 | 0.79 | ALDH1A1 (0.45) | KMT2AMAPTHPGDALDH1A1NPC1 | |
| SCHEMBL14703370 | 0.78 | ALDH1A1 (0.46) | KMT2AMAPTLMNAALDH1A1RAB9A | |
| SCHEMBL14703671 | 0.78 | KMT2A (0.48) | KMT2ALMNAALDH1A1NPC1RAB9A | |
| SCHEMBL7696764 | 0.77 | KMT2A (0.51) | KMT2AMAPTLMNAHPGDALDH1A1 | |
| SCHEMBL14703433 | 0.76 | MEN1 (0.43) | KMT2AMAPTMEN1L3MBTL1 | |
| SCHEMBL14703426 | 0.75 | MEN1 (0.52) | KMT2ALMNAHPGDALDH1A1NPC1 | |
| SCHEMBL14703476 | 0.75 | KIF11 (0.40) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742020-B1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | IMMUNOMET THERAPEUTICS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9321742-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321742-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140296222-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| WO-2013022279-A2 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO., LTD. (KR) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | PRKAG1, GCKR, GPR119 | KMT2A 1377/4885MAPT 3041/4885LMNA 2589/4885 |
| US-20140296222-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, BACE2 | KMT2A 3376/4885MAPT 14/4885LMNA 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.